1
|
Pritchard CC, Mateo J, Walsh MF, De Sarkar
N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R,
et al: Inherited DNA-repair gene mutations in men with metastatic
prostate cancer. N Engl J Med. 375:443–453. 2016. View Article : Google Scholar
|
2
|
Wu J, Gu W, Qin X, Lin G, Dai B, Zhu Y and
Ye D: Study on BRCA1/2 and ATM germline mutations in the Chinese
prostate cancer patients. Chin Oncol. 28:584–589. 2018.(In
Chinese).
|
3
|
Bardai A, Overwater E and Aalfs CM:
Germline mutations in predisposition genes in pediatric cancer. N
Engl J Med. 374:1390–1391. 2016. View Article : Google Scholar
|
4
|
Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang
J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, et al:
Pathogenic germline variants in 10,389 adult cancers. Cell.
173:355–370. 2018. View Article : Google Scholar
|
5
|
Keel SB, Scott A, Sanchez-Bonilla M, Ho
PA, Gulsuner S, Pritchard CC, Abkowitz JL, King MC, Walsh T and
Shimamura A: Genetic features of myelodysplastic syndrome and
aplastic anemia in pediatric and young adult patients.
Haematologica. 101:1343–1350. 2016. View Article : Google Scholar
|
6
|
Churpek JE, Pyrtel K, Kanchi KL, Shao J,
Koboldt D, Miller CA, Shen D, Fulton R, O'Laughlin M, Fronick C, et
al: Genomic analysis of germ line and somatic variants in familial
myelodysplasia/acute myeloid leukemia. Blood. 126:2484–2490. 2015.
View Article : Google Scholar
|
7
|
Göhler S, Da Silva Filho MI, Johansson R,
Enquist-Olsson K, Henriksson R, Hemminki K, Lenner P and Försti A:
Functional germline variants in driver genes of breast cancer.
Cancer Causes Control. 28:259–271. 2017. View Article : Google Scholar
|
8
|
Rahbari R, Wuster A, Lindsay SJ, Hardwick
RJ, Alexandrov LB, Al Turki S, Dominiczak A, Morris A, Porteous D,
Smith B, et al: Timing, rates and spectra of human germline
mutation. Nat Genet. 48:126–133. 2016. View Article : Google Scholar
|
9
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the world health organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar
|
10
|
Pabst T, Eyholzer M, Haefliger S, Schardt
J and Mueller BU: Somatic CEBPA mutations are a frequent second
event in families with germline CEBPA mutations and familial acute
myeloid leukemia. J Clin Oncol. 26:5088–5093. 2008. View Article : Google Scholar
|
11
|
Li HY, Deng DH, Huang Y, Ye FH, Huang LL,
Xiao Q, Zhang B, Ye BB, Lai YR, Mo ZN and Liu ZF: Favorable
prognosis of biallelic CEBPA gene mutations in acute myeloid
leukemia patients: A meta-analysis. Eur J Haematol. 94:439–448.
2015. View Article : Google Scholar
|
12
|
Tawana K, Wang J, Renneville A, Bödör C,
Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades
P, et al: Disease evolution and outcomes in familial AML with
germline CEBPA mutations. Blood. 126:1214–1223. 2015. View Article : Google Scholar
|
13
|
Taskesen E, Bullinger L, Corbacioglu A,
Sanders MA, Erpelinck CA, Wouters BJ, van der Poel-van de
Luytgaarde SC, Damm F, Krauter J, Ganse A, et al: Prognostic
impact, concurrent genetic mutations, and gene expression features
of AML with CEBPA mutations in a cohort of 1182
cytogenetically normal AML patients: Further evidence for CEBPA
double mutant AML as a distinctive disease entity. Blood.
117:2469–2475. 2011. View Article : Google Scholar
|
14
|
Stelljes M, Corbacioglu A, Schlenk RF,
Döhner K, Frühwald MC, Rossig C, Ehlert K, Silling G, Müller-Tidow
C, Juergens H, et al: Allogeneic stem cell transplant to eliminate
germline mutations in the gene for CCAAT-enhancer-binding protein α
from hematopoietic cells in a family with AML. Leukemia.
25:1209–1210. 2011. View Article : Google Scholar
|
15
|
Ram J, Flamm G, Balys M, Sivagnanalingam
U, Rothberg PG, Iqbal A, Myers JR, Corbett A, Ashton JM and Mendler
JH: Index case of acute myeloid leukemia in a family harboring a
novel CEBPA germ line mutation. Blood Adv. 1:500–503. 2017.
View Article : Google Scholar
|
16
|
Nanri T, Uike N, Kawakita T, Iwanaga E,
Mitsuya H and Asou N: A family harboring a germ-line N-terminal
C/EBPalpha mutation and development of acute myeloid leukemia with
an additional somatic C-terminal C/EBPalpha mutation. Genes
Chromosomes Cancer. 49:237–241. 2010.
|
17
|
Greif PA, Dufour A, Konstandin NP,
Ksienzyk B, Zellmeier E, Tizazu B, Sturm J, Benthaus T, Herold T,
Yaghmaie M, et al: GATA2 zinc finger 1 mutations associated
with biallelic CEBPA mutations define a unique genetic entity of
acute myeloid leukemia. Blood. 120:395–403. 2012. View Article : Google Scholar
|
18
|
Ripperger T, Steinemann D, Göhring G,
Finke J, Niemeyer CM, Strahm B and Schlegelberger B: A novel
pedigree with heterozygous germline RUNX1 mutation causing familial
MDS-related AML: Can these families serve as a multistep model for
leukemic transformation? Leukemia. 23:1364–1366. 2009. View Article : Google Scholar
|
19
|
Schmit JM, Turner DJ, Hromas RA, Wingard
JR, Brown RA, Li Y, Li MM, Slayton WB and Cogle CR: Two novel RUNX1
mutations in a patient with congenital thrombocytopenia that
evolved into a high grade myelodysplastic syndrome. Leuk Res Rep.
4:24–27. 2015.
|
20
|
Antony-Debré I, Manchev VT, Balayn N,
Bluteau D, Tomowiak C, Legrand C, Langlois T, Bawa O, Tosca L and
Tachdjian G: Level of RUNX1 activity is critical for leukemic
predisposition but not for thrombocytopenia. Blood. 125:930–940.
2015. View Article : Google Scholar
|
21
|
Dowdy CR, Frederick D, Zaidi SK, Colby JL,
Lian JB, van Wijnen AJ, Gerstein RM, Stein JL and Stein GS: A
germline point mutation in RUNX1 uncouples its role in definitive
hematopoiesis from differentiation. Exp Hematol. 41:980–991. 2013.
View Article : Google Scholar
|
22
|
Wlodarski MW, Hirabayashi S, Pastor V,
Starý J, Hasle H, Masetti R, Dworzak M, Schmugge M, van den
Heuvel-Eibrink M, Ussowicz M, et al: Prevalence, clinical
characteristics, and prognosis of GATA2-related
myelodysplastic syndromes in children and adolescents. Blood.
127:1387–1397. 2016. View Article : Google Scholar
|
23
|
Cortés-Lavaud X, Landecho MF, Maicas M,
Urquiza L, Merino J, Moreno-Miralles I and Oder MD: GATA2 germline
mutations impair GATA2 transcription, causing haploinsufficiency:
Functional analysis of the p.Arg396Gln mutation. J Immunol.
194:2190–2198. 2015. View Article : Google Scholar
|
24
|
Chong CE, Venugopal P, Stokes PH, Lee YK,
Brautigan PJ, Yeung DT, Babic M, Engler GA, Lane SW,
Klingler-Hoffmann M, et al: Differential effects on gene
transcription and hematopoietic differentiation correlate with
GATA2 mutant disease phenotypes. Leukemia. 32:194–202. 2018.
View Article : Google Scholar
|
25
|
Soukup AA, Zheng Y, Mehta C, Wu J, Liu P,
Cao M, Hofmann I, Zhou Y, Zhang J, Johnson KD, et al:
Single-nucleotide human disease mutation inactivates a
blood-regenerative GATA2 enhancer. J Clin Invest. 129:1180–1192.
2019. View Article : Google Scholar
|
26
|
McReynolds LJ, Yang Y, Wong HY, Tang J,
Zhang Y, Mulé MP, Daub J, Palmer C, Foruraghi L, Liu Q, et al:
MDS-associated mutations in germline GATA2 mutated patients with
hematologic manifestations. Leuk Res. 76:70–75. 2019. View Article : Google Scholar
|
27
|
West RR, Hsu AP, Holland SM,
Cuellar-Rodriguez J and Hickstein DD: Acquired ASXL1 mutations are
common in patients with inherited GATA2 mutations and correlate
with myeloid transformation. Haematologica. 99:276–281. 2014.
View Article : Google Scholar
|
28
|
Green CL, Tawana K, Hills RK, Bödör C,
Fitzgibbon J, Inglott S, Ancliff P, Burnett AK, Linch DC and Gale
RE: GATA2 mutations in sporadic and familial acute myeloid
leukaemia patients with CEBPA mutations. Br J Haematology.
161:701–705. 2013. View Article : Google Scholar
|
29
|
Cheah JJ, Hahn CN, Hiwase DK, Scott HS and
Brown AL: Myeloid neoplasms with germline DDX41 mutation. Int J
Hematol. 106:163–174. 2017. View Article : Google Scholar
|
30
|
Quesada AE, Routbort MJ, DiNardo CD,
Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z,
Yin CC, Loghavi S, et al: DDX41 mutations in myeloid neoplasms are
associated with male gender, TP53 mutations and high-risk disease.
Am J Hematol. 94:757–766. 2019.
|
31
|
Galera P, Dulau-Florea A and Calvo KR:
Inherited thrombocytopenia and platelet disorders with germline
predisposition to myeloid neoplasia. Int J Lab Hematol. 41:131–141.
2019. View Article : Google Scholar
|
32
|
Perez Botero J, Oliveira JL, Chen D,
Reichard KK, Viswanatha DS, Nguyen PL, Pruthi RK, Majerus J, Gada
P, Gangat N, et al: ASXL1 mutated chronic myelomonocytic leukemia
in a patient with familial thrombocytopenia secondary to germline
mutation in ANKRD26. Blood Cancer J. 5:e3152015. View Article : Google Scholar
|
33
|
Romero D: Haematological cancer: ETV6
germline mutation-a risk for ALL. Nat Rev Clin Oncol. 13:42016.
View Article : Google Scholar
|
34
|
Pauli S, Steinemann D, Dittmann K,
Wienands J, Shoukier M, Möschner M, Burfeind P, Manukjan G, Göhring
G and Escherich G: Occurrence of acute lymphoblastic leukemia and
juvenile myelomonocytic leukemia in a patient with Noonan syndrome
carrying the germline PTPN11 mutation p.E139D. Am J Med Genet A.
158:652–658. 2012. View Article : Google Scholar
|
35
|
Bradley CP, Chen C, Oetjen KA, Yan C,
Panjwani R, Hauffe S, Calvo KR, Yuan C, Patel PA, Montgomery ND, et
al: Persistence of skewed X-chromosome inactivation in pre-B acute
lymphoblastic leukemia of a female ATRX mutation carrier. Blood
Adv. 3:2627–2631. 2019. View Article : Google Scholar
|
36
|
Hoshino A, Okada S, Yoshida K, Nishida N,
Okuno Y, Ueno H, Yamashita M, Okano T, Tsumura M, Nishimura S, et
al: Abnormal hematopoiesis and autoimmunity in human subjects with
germline IKZF1 mutations. J Allergy Clin Immunol. 140:223–231.
2017. View Article : Google Scholar
|
37
|
Chen C, Bartenhagen C, Gombert M, Okpanyi
V, Binder V, Röttgers S, Bradtke J, Teigler-Schlegel A, Harbott J,
Ginzel S, et al: Next-generation-sequencing of recurrent childhood
high hyperdiploid acute lymphoblastic leukemia reveals mutations
typically associated with high risk patients. Leuk Res.
39:990–1001. 2015. View Article : Google Scholar
|
38
|
Loughran SJ, Kruse EA, Hacking DF, de
Graaf CA, Hyland CD, Willson TA, Henley KJ, Ellis S, Voss AK,
Metcalf D, et al: The transcription factor erg is essential for
definitive hematopoiesis and the function of adult hematopoietic
stem cells. Nat Immunol. 9:810–819. 2008. View Article : Google Scholar
|
39
|
Rehman AU, Rahman MU, Khan MT, Saud S, Liu
H, Song D, Sultana P, Wadood A and Chen HF: The landscape of
protein tyrosine phosphatase (Shp2) and cancer. Curr Pharm Des.
24:3767–3777. 2018. View Article : Google Scholar
|
40
|
van Scherpenzeel Thim V, Remacle S, Picard
J, Cornu G, Gofflot F, Rezsohazy R and Verellen-Dumoulin C:
Mutation analysis of the HOX paralogous 4–13 genes in children with
acute lymphoid malignancies: Identification of a novel germline
mutation of HOXD4 leading to a partial loss-of-function. Hum Mutat.
25:384–395. 2005. View Article : Google Scholar
|
41
|
Perez-Garcia A, Ambesi-Impiombato A,
Hadler M, Rigo I, LeDuc CA, Kelly K, Jalas C, Paietta E, Racevskis
J, Rowe JM, et al: Genetic loss of SH2B3 in acute lymphoblastic
leukemia. Blood. 122:2425–2432. 2013. View Article : Google Scholar
|
42
|
Qian M, Cao X, Devidas M, Yang W, Cheng C,
Dai Y, Carroll A, Heerema NA, Zhang H, Moriyama T, et al: TP53
germline variations influence the predisposition and prognosis of
B-cell acute lymphoblastic leukemia in children. J Clin Oncol.
36:591–599. 2018. View Article : Google Scholar
|
43
|
Chen L, Xu B, Long X, Gu J, Lou Y, Wang D,
Cao Y, Wang N, Li C, Wang G, et al: CAR T-cell therapy for a
relapsed/refractory acute B-cell lymphoblastic lymphoma patient in
the context of li-fraumeni syndrome. J Immunother Cancer.
8:e0003642020. View Article : Google Scholar
|
44
|
Hamadou WS, Abed RE, Besbes S, Bourdon V,
Fabre A, Youssef YB, Laatiri MA, Eisinger F, Mari V, Gesta P, et
al: Familial hematological malignancies: ASXL1 gene investigation.
Clin Transl Oncol. 18:385–390. 2016. View Article : Google Scholar
|
45
|
Seiter K, Htun K, Baskind P and Liu Z:
Acute myeloid leukemia in a father and son with a germline mutation
of ASXL1. Biomark Res. 6:72018. View Article : Google Scholar
|
46
|
Zink F, Stacey SN, Norddahl GL, Frigge ML,
Magnusson OT, Jonsdottir I, Thorgeirsson TE, Sigurdsson A,
Gudjonsson SA, Gudmundsson J, et al: Clonal hematopoiesis, with and
without candidate driver mutations, is common in the elderly.
Blood. 130:742–752. 2017. View Article : Google Scholar
|
47
|
Pan LL, Huang YM, Wang M, Zhuang Xe, Luo
Df, Guo Sc, Zhang Zs, Huang Q, Lin Sl and Wang Sy: Positional
cloning and next-generation sequencing identified a TGM6 mutation
in a large Chinese pedigree with acute myeloid leukaemia. Eur J Hum
Genet. 23:218–223. 2015. View Article : Google Scholar
|
48
|
Hahn CN, Babic M, Schreiber AW, Kutyna MM,
Wee LA, Brown AL, Perugini M, Singhal D, Hiwase S, Feng J, et al:
Rare and common germline variants contribute to occurrence of
myelodysplastic syndrome. Blood. 126:16442015. View Article : Google Scholar
|
49
|
Abelson S, Collord G, Ng SW, Weissbrod O,
Cohen NM, Niemeyer E, Barda N, Zuzarte PC, Heisler L,
Sundaravadanam Y, et al: Prediction of acute myeloid leukaemia risk
in healthy individuals. Nature. 559:400–404. 2018. View Article : Google Scholar
|
50
|
Carter H, Marty R, Hofree M, Gross AM,
Jensen J, Fisch KM, Wu X, DeBoever C, Van Nostrand EL, Song Y, et
al: Interaction landscape of inherited polymorphisms with somatic
events in cancer. Cancer Discov. 7:410–423. 2017. View Article : Google Scholar
|
51
|
Bluteau O, Sebert M, Leblanc T, de Latour
RP, Quentin S, Lainey E, Hernandez L, Dalle JH, de Fontbrune FS,
Lengline E, et al: A landscape of germ line mutations in a cohort
of inherited bone marrow failure patients. Blood. 131:717–732.
2018. View Article : Google Scholar
|
52
|
Taeubner J, Wieczorek D, Yasin L, Brozou
T, Borkhardt A and Kuhlen M: Penetrance and expressivity in
inherited cancer predisposing syndromes. Trends Cancer. 4:718–728.
2018. View Article : Google Scholar
|
53
|
Sabattini E, Bacci F, Sagramoso C and
Pileri SA: WHO classification of tumours of haematopoietic and
lymphoid tissues in 2008: An overview. Pathologica. 102:83–87.
2010.
|
54
|
Drazer MW, Kadri S, Sukhanova M, Patil SA,
West AH, Feurstein S, Calderon DA, Jones MF, Weipert CM, Daugherty
CK, et al: Prognostic tumor sequencing panels frequently identify
germ line variants associated with hereditary hematopoietic
malignancies. Blood Adv. 2:146–150. 2018. View Article : Google Scholar
|
55
|
Király AP, Kállay K, Gángó A, Kellner A,
Egyed M, Szőke A, Kiss R, Vályi-Nagy I, Csomor J, Matolcsy A and
Bödör C: Familial acute myeloid leukemia and myelodysplasia in
hungary. Pathol Oncol Res. 24:83–88. 2018. View Article : Google Scholar
|
56
|
Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W,
Zhang L, Wang Y, Liu L, Wu K, et al: First report of multiple CEBPA
mutations contributing to donor origin of leukemia relapse after
allogeneic hematopoietic stem cell transplantation. Blood.
117:5257–5260. 2011. View Article : Google Scholar
|
57
|
Galera P, Hsu AP, Wang W, Droll S, Chen R,
Schwartz JR, Klco JM, Arai S, Maese L and Zerbe C: Donor-derived
MDS/AML in families with germline GATA2 mutation. Blood.
132:1994–1998. 2018. View Article : Google Scholar
|